ANTIVIRAL DRUG

$19,625P41FY2011RRNIH

Baylor College Of Medicine, Houston TX

Investigators

Linked publications & trials

Paper 31063459 Paper 30405903 Paper 29559513 Paper 27570571 Paper 27563367 Paper 27563162 Paper 27563154 Paper 27540272 Paper 27352937 Paper 26913144 Paper 26469938 Paper 25844145 Paper 25809480 Paper 25697530 Paper 25550159 Paper 25429975 Paper 25040172 Paper 24819597 Paper 24750465 Paper 24646888 Paper 24160736 Paper 23967136 Paper 23839099 Paper 23831288 Paper 23746846 Paper 23707684 Paper 23698020 Paper 23616213 Paper 23541894 Paper 23390418 Paper 23360752 Paper 23178122 Paper 23086203 Paper 23043292 Paper 23000701 Paper 22989153 Paper 22967226 Paper 22842542 Paper 22696403 Paper 22696402 Paper 22472420 Paper 22405004 Paper 22404935 Paper 22325770 Paper 22297510 Paper 22297509 Paper 22285189 Paper 22118658 Paper 22045336 Paper 22037305 Paper 21852942 Paper 21845206 Paper 21829444 Paper 21829169 Paper 21827954 Paper 21827945 Paper 21787787 Paper 21752918 Paper 21752915 Paper 21731614 Paper 21690369 Paper 21679911 Paper 21619932 Paper 21565698 Paper 21532589 Paper 21516262 Paper 21506171 Paper 21501818 Paper 21488620 Paper 21389566 Paper 21336265 Paper 21296162 Paper 21241893 Paper 21220301 Paper 21218176 Paper 21147776 Paper 21124809 Paper 21121065 Paper 21106752 Paper 21038867 Paper 20947014 Paper 20933521 Paper 20888963 Paper 20888467 Paper 20885381 Paper 20843027 Paper 20709082 Paper 20696391 Paper 20631855 Paper 20556220 Paper 20543830 Paper 20529921 Paper 20495682 Paper 20462491 Paper 20454544 Paper 20376194 Paper 20356853 Paper 20338243 Paper 20300489 Paper 20194787

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Medimmune, Inc. has an FAB which tightly binds to a specific viral F protein, which acts as an antiviral agent. While the FAB has been biochemically characterized, structurally, it remains unclear exactly how the binding occurs. This knowledge would be valuable to Medimmune in development of future similar products. Medimmune is providing F protein trimers with bound antibodies in aqueous buffer for cryo-EM characterization. We attempt to solve the structure at the highest resolution possible, hopefully to subnanometer resolution. Medimmune has awarded Dr. Ludtke a small grant to study this interaction in collaboration with Dr. Oganesyan.

View original record on NIH RePORTER →